Endo: Accessing Primary Care through Specialist Marketing
Executive Summary
Endo believes its specialist approach to pain management is key to eventually winning over a respectable market share in primary care, given that it can successfully differentiate Frova, the sixth-in-class migraine treatment it licensed from Vernalis in July 2004. Skeptics point to the failure of previous owners of Frova to gain the drug any primary care notice since its launch in mid-2002. Endo chairman and CEO Carol Ammon contends that the company can inexpensively exploit the unique characteristics of the drug in the medical community and succeed where others have failed through a singular focus on specialist medicine that she claims as its bailiwick.
You may also be interested in...
The Shake Up At Endo Pharma
Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.
The Shake Up At Endo Pharma
Endo Pharma CEO Dave Holveck is diversifying the company from its core pain franchise into seemingly unrelated fields. Critics argue that he's neglecting its core strengths and acquiring mediocre assets, but he says such moves are necessary to address marketplace shifts.
Reliant: The Expensive Opportunities in Primary Care
Reliant's business model -- building a new company to sell the primary care products that looked too puny for Big Pharma -- posed management and financing challenges that almost killed the company. It's turned around, thanks to new management and a product in a hot area-lipids. But what's really got its investors excited: the opportunities posed by late-stage primary-care failures at Big Pharmas, who are now looking for market-proven products. And those Big Pharmas can help pay the acquisition cost by dismantling the costly infrastructure created to prove the product's value in the first place.